Top Markets
Coin of the day
Bio-Path Holdings, Inc. Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc.

BPTH
Kedudukan dalam Saham #39844
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on... Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Harga Saham
$0.035
Disegerakkan terakhir: 2026-08-13
Modal Pasaran
$326.98K
Perubahan (1 hari)
-12.50%
Perubahan (1 tahun)
-74.55%
Negara
US
Perdagangan Bio-Path Holdings, Inc. (BPTH)

Kategori

Nisbah P/S bagi Bio-Path Holdings, Inc. (BPTH)
Nisbah P/S pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini Bio-Path Holdings, Inc., nisbah P/S semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/S syarikat ialah 0.
Sejarah nisbah P/S untuk Bio-Path Holdings, Inc. dari 2026 hingga 2026
Nisbah P/S pada akhir setiap tahun
Tahun Nisbah P/S Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/S untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/S Perbezaan Nisbah P/S Negara
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE